Evidence map›Paper›PMID 39077685›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

NODDI in gray matter is a sensitive marker of aging and early AD changes.

Xi Yu, Scott A Przybelski, Robert I Reid, Timothy G Lesnick, Sheelakumari Raghavan, Jonathan Graff-Radford, Val J Lowe, Kejal Kantarci, David S Knopman, Ronald C Petersen and 2 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. Article
  3. Gray Matter Microstructure Measured Using Diffusion Imaging as a Biomarker of Severity in Lewy Body Diseases.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  4. Review
  5. Superficial white matter and gray matter jointly support cognition among older adults in India.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Predicting progression from MCI to dementia using cortical disarray measurement from diffusion MRI.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xi YuDepartment of Physiology and Biomedical Engineering Mayo Clinic Rochester Minnesota USA.ORCID https://orcid.org/0000-0002-1024-4653
Scott A PrzybelskiDepartment of Health Sciences Research Division of Biomedical Statistics and Informatics Mayo Clinic-Rochester Rochester Minnesota USA.
Robert I ReidDepartment of Health Sciences Research Division of Biomedical Statistics and Informatics Mayo Clinic-Rochester Rochester Minnesota USA.
Timothy G LesnickDepartment of Health Sciences Research Division of Biomedical Statistics and Informatics Mayo Clinic-Rochester Rochester Minnesota USA.
Sheelakumari RaghavanDepartment of Radiology Mayo Clinic-Rochester Rochester Minnesota USA.
Jonathan Graff-RadfordDepartment of Neurology Mayo Clinic-Rochester Rochester Minnesota USA.
Val J LoweDepartment of Radiology Mayo Clinic-Rochester Rochester Minnesota USA.
Kejal KantarciDepartment of Radiology Mayo Clinic-Rochester Rochester Minnesota USA.
David S KnopmanDepartment of Neurology Mayo Clinic-Rochester Rochester Minnesota USA.
Ronald C PetersenDepartment of Neurology Mayo Clinic-Rochester Rochester Minnesota USA.
Clifford R JackDepartment of Radiology Mayo Clinic-Rochester Rochester Minnesota USA.
Prashanthi VemuriDepartment of Radiology Mayo Clinic-Rochester Rochester Minnesota USA.

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Development, Validation, and Application of an Imaging based CVD ScaleR01NS097495 · NINDS · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 2016 to 2020
$2.9M
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementiasRF1AG069052 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, MIELKE, MICHELLE M · 2021 to 2021
$2.4M
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementiasR01AG069052 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, MIELKE, MICHELLE M · 2024 to 2025
$1.5M
NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG056366NIA NIH HHS R01 AG069052NIA NIH HHS R37 AG011378NIA NIH HHS RF1 AG069052NIA NIH HHS U01 AG006786NINDS NIH HHS R01 NS097495
6 · The paper itself

Abstract

introductionAge-related and Alzheimer's disease (AD) dementia-related neurodegeneration impact brain health. While morphometric measures from T1-weighted scans are established biomarkers, they may be less sensitive to earlier changes. Neurite orientation dispersion and density imaging (NODDI), offering biologically meaningful interpretation of tissue microstructure, may be an advanced brain health biomarker.

methodsWe contrasted regional gray matter NODDI and morphometric evaluations concerning their correlation with (1) age, (2) clinical diagnosis stage, and (3) tau pathology as assessed by AV1451 positron emission tomography.

resultsOur study hypothesizes that NODDI measures are more sensitive to aging and early AD changes than morphometric measures. One NODDI output, free water fraction (FWF), showed higher sensitivity to age-related changes, generally better effect sizes in separating mild cognitively impaired from cognitively unimpaired participants, and stronger associations with regional tau deposition than morphometric measures. DISCUSSION: These findings underscore NODDI's utility in capturing early neurodegenerative changes and enhancing our understanding of aging and AD. Highlights: Neurite orientation dispersion and density imaging can serve as an effective brain health biomarker for aging and early Alzheimer's disease (AD).Free water fraction has higher sensitivity to normal brain aging.Free water fraction has stronger associations with early AD and regional tau deposition.

Indexed as

brain agingdiffusion magnetic resonance imagingearly Alzheimer's disease dementianeurite orientation dispersion and density imaging

Identifiers

PMID39077685
PMCPMC11284641

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.